Teva
CompanyIsraelFounded 1901
Teva develops 12 assets, the furthest approved (glatiramer acetate in clinically isolated syndrome). Mostly small molecule and peptide acting on AVPR1A, AVPR1B and AVPR2; based in Israel, founded in 1901.
- 12
- Assets
- Furthest stage
- Approved
- 202
- Trials
- 46
- Signals
Pipeline
12Modulates immune responses to myelin, reducing inflammatory damage in multiple sclerosis.
Approved, Peptide, clinically isolated syndrome, Relapsing Forms of Multiple Sclerosis
Losartan potassium/Hydrochlorothiazide
Angiotensin II receptor antagonist combined with a thiazide diuretic to lower blood pressure.
Approved, Small molecule, hypertension, left ventricular hypertrophy
Activates vasopressin V2 receptors to increase renal water reabsorption and reduce urine production.
Approved, not sold in the US, Peptide, AVPR1A, AVPR1B, nocturia (Phase 3), nocturnal enuresis (Phase 3)
9 more assets
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
112 trials
In the full profile
- Evidence behind the mechanisms9
- Trials273
- Signals20
- Similar companies6
Papers
ENDO 2025 abstract, Oct 23, 2025
PloS one, Sep 11, 2025
Journal of the American Geriatrics Society, Aug 11, 2025
Scientific reports, Jan 20, 2024
Neurobiology of disease, Nov 8, 2016